Pancreatic sensory phenotyping may help sort out who benefits from invasive pain relief in chronic pancreatitis
Pain in chronic pancreatitis is one of the most stubborn problems in gastrointestinal medicine, especially when pancreatic duct obstruction pushes clinicians toward endoscopic therapy or surgery. Even after a technically successful procedure, pain relief can be incomplete, delayed, or absent. The central issue is not simply whether the duct can be decompressed; it is whether the patient’s nervous system has already been remodeled by persistent nociceptive input.
This observational clinical trial is built around that problem. Investigators will test whether pretreatment pancreatic quantitative sensory testing, or P-QST, can classify patients into phenotypes that predict the likelihood of pain improvement after invasive treatment. The protocol reflects a practical clinical need: the same intervention can look appropriate on imaging and still fail to relieve pain if the dominant driver has shifted from peripheral obstruction to central sensitisation.
Why duct decompression does not always translate into pain control
In chronic pancreatitis, recurrent pain signals can promote neuronal hyperexcitability and central nervous system sensitisation. Once that process is established, the pain system may amplify incoming signals long after the original injury has become partially addressable. In that setting, endoscopic decompression or surgery may clear the obstruction, yet pain behavior can remain uncoupled from the anatomy.
P-QST tries to capture that biology at the bedside. The method uses standardised stimulation to phenotype the pain system in chronic pancreatitis and separates patients into three mutually exclusive groups: no central sensitisation, segmental sensitisation within the pancreatic viscerotome, and widespread hyperalgesia suggestive of supraspinal central sensitisation. Those distinctions matter because they map onto different mechanisms. A patient with pain driven mainly by a peripheral pancreatic lesion may have a very different response pattern from someone whose nociceptive network has become globally sensitized.
The trial will enroll 150 patients across three centers
The study will enroll 150 patients from the University of Pittsburgh, Johns Hopkins, and Indiana University. Each participant will undergo pretreatment phenotyping with P-QST before receiving invasive care for painful pancreatic duct obstruction. The treatment pathway will consist of pancreatic endotherapy or surgery, chosen for clearance of the obstructed ductal system.
This is an observational design rather than an interventional randomization study, so the protocol is not asking whether endotherapy is better than surgery. It is asking a narrower and more clinically useful question: can a sensory phenotype obtained before treatment forecast who is likely to improve? In routine practice, that sort of information could change counseling, expectations, and procedural selection, especially when the burden of chronic pain, opioid use, and impaired quality of life is high.
The multicenter setup also increases the relevance of the findings. Chronic pancreatitis care is often distributed across specialized referral centers, and invasive treatment decisions are not made in a single uniform setting. A predictive model that can perform across sites would carry more practical value than a center-specific observation.
Pain score at 6 months will anchor the primary endpoint
The primary outcome is the average pain score over the preceding 7 days measured by Numeric Rating Scale at 6 months after the intervention. This endpoint keeps the study focused on the symptom that drives most of the treatment burden. Chronic pancreatitis pain is not a laboratory abstraction; it dictates function, sleep, nutrition, and the trajectory of escalating analgesic use.
A 6-month horizon is clinically meaningful because it allows time for procedural recovery and for pain patterns to stabilize after ductal decompression. Short-term postoperative or post-endoscopic changes can be misleading, especially in a disorder where inflammation, neuropathic change, and behavioral adaptation overlap. The protocol also includes pain and quality-of-life assessments at 3, 6, and 12 months, which should help capture whether any apparent response is durable rather than transient.
Opioid use and patient-reported outcomes will add clinical context
Secondary outcomes include changes in opioid use during follow-up and patient-reported outcomes in pain and quality of life at 3, 6, and 12 months. Those measures are important because a reduction in average pain score alone does not always reflect the full bedside picture. A patient may report modest improvement while still escalating rescue medication, or may lower opioid exposure while maintaining acceptable function despite residual symptoms.
By tracking opioid use alongside patient-reported outcomes, the study acknowledges how chronic pancreatitis pain is actually managed in real clinics. The goal is not merely a statistical shift on a rating scale. It is to identify a phenotype that can help clinicians predict whether an invasive procedure will translate into meaningful symptom relief and a lighter pharmacologic burden.
Exploratory modeling could move this from phenotype to prediction
An exploratory aim of the trial is the creation of a model for individualized prediction of response to invasive treatment. This is where the protocol becomes especially interesting from a translational standpoint. If pretreatment sensory testing can be combined into a usable prediction tool, clinicians may eventually move beyond binary decisions based only on ductal anatomy and toward a more biologically informed framework.
The pathophysiology supports that direction. Persistent pancreatic pain can generate central sensitisation, and once the nervous system has become hyperresponsive, mechanical decompression may not fully reset the pain circuit. A model incorporating P-QST phenotype could help identify patients whose pain is likely to remain pain-driven after the obstruction is treated, as well as those whose symptoms are more likely to improve once the peripheral driver is removed.
Ethical approval and dissemination are already in place
The study has approval from the University of Pittsburgh Institutional Review Board. Results will be reported and disseminated in line with National Institutes of Health policies. The registration number is NCT04996628.
Because this is a protocol, there are no efficacy results yet. The unanswered clinical problem sits squarely in front of the investigators: whether a standardized sensory phenotype can predict pain response after endoscopic therapy or surgery in painful chronic pancreatitis. If the signal is strong, the next challenge will be translating it into a model that is accurate enough for real-world treatment selection, not just statistically interesting on paper.